Weilemann LS. [Not all drugs are the same].
Med Klin Intensivmed Notfmed 2013;
108:484-90. [PMID:
23974649 DOI:
10.1007/s00063-013-0219-1]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Accepted: 07/02/2013] [Indexed: 10/26/2022]
Abstract
Drug use has changed dramatically in recent years. Classic drugs such as marijuana, heroin, and cocaine are being pushed progressively into the background. Consumer behavior has also changed and so-called designer drugs dominate the market. Designer drugs are synthetic or semi-synthetic drugs based on a well-known substance. Mostly amphetamine derivates, synthetic cannabinoids, and synthetic cathinone are used. Legal monitoring capabilities are limited, since these substances are so-called legal highs and are commercially available. A ban often follows a latency period. Estimating the risk is difficult, and the problem of intoxication increases. This overview presents the activity profiles and risks of classic and new drugs.
Collapse